KEY WORDS: aneurysm ■ cardiomyopathy ■ drug-eluting stent ■ heart failure ■ mechanical circulatory support 
L eft ventricular (LV) assist device implantation is considered to be a therapeutic option only in highly selected cases of giant LV aneurysm because of concerns regarding tissue consistence, potential mobilization of intracardiac thrombotic material, and thrombogenic properties of aneurysmal tissue. 1 To facilitate secure placement of the inflow cannula, avoid embolic events, and attain LV remodeling, implantation of the device is performed in combination with LV reconstruction.
Patient Presentation
A 51-year-old, white male patient was admitted for evaluation of an end-stage heart failure because of ischemic cardiomyopathy. Echocardiographic examination revealed severe systolic dysfunction (LV ejection fraction of 10%), significant thrombus in the giant LV aneurysm, and a contained apical wall rupture resulting from acute myocardial infarction (Figure) . Despite interventional revascularization of the left anterior descending artery with a drug-eluting stent and medical therapy, including inotropic support, the patient continued to decline to functional New York Heart Association class IV, Interagency Registry for Mechanically Assisted Circulatory Support level 2. Surgical options were limited. Conventional surgical excision of the aneurysm was deemed unlikely to be successful. Orthotopic heart transplantation on inotrope support seemed to be unrealistic, given the long waiting time because of limited availability of donors. Finally, the option of implementing total artificial therapy was dismissed by the patient and his relatives. We instead decided to perform implantation of the HeartMate III device (Thoratec Inc) as a bridge to transplantation.
Surgical Procedure
The HeartMate III device was conventionally implanted as an LV assist device. We chose to place the inflow cannula at the perforation site, just laterally to the LV apex. After removal of the core, ventricular cavity was inspected and thrombotic material adherent to the LV wall was removed. The sewing cuff was fixed on the LV using eight 2-0 polyester sutures with large teflon pledgets. Aneurysmal fibrous scar tissue proved to be consistent enough to withstand strain of the sutures. After placement of the inflow cannula in the LV cavity and anastomosis of the outflow graft with the ascending aorta, the driveline was tunneled and connected to the external driver. The patient was weaned from cardiopulmonary bypass, and pump support was initiated.
Postoperative Course
Postoperative course was uneventful. Patient was successfully weaned from mechanical ventilation at postoperative day 1 and transferred to normal-care station at postoperative day 4. Transthoracic echocardiography revealed proper positioning of the inflow cannula. Because of previous left anterior descending artery revascularization with a drug-eluting stent, we initiated triple oral anticoagulation (warfarin with a target International Normalized Ratio between 2.5 and 3.0, aspirin 100 mg, and clopidogrel 75 mg daily). Patient was discharged from the hospital on postoperative day 33 and to date (184 days after surgery) has had no thromboembolic or hemorrhagic events. Serial echocardiograms done during follow-up showed stable alignment of the inflow cannula. Clinical state and quality of life improved markedly (New York Heart Association class I).
Conclusion
End-stage heart failure because of ischemic cardiomyopathy with an LV aneurysm after a myocardial infarction still poses a challenge to implanting an LV assist device. The focus of concerns have been regarding fixation of the inflow cannula in thin myocardial tissue and possible formation of thrombi afterward, resulting in pump thrombosis and cerebrovascular events.
1 Concomitant LV remodeling either by the means of endoventricular circular patch plasty (Dor procedure) 2 or by the means of partial LV reconstruction by placing pledgeted sutures around the aneurysmatic sac 3 or performing a Fontan stitch around a Hegar dilator 4 has been, therefore, promoted as an option to facilitate secure cannula fixation and exclude any thromboembolic events originating from debris located in the aneurysmal cavity. To our knowledge, this is the first case reporting favorable midterm outcome after conventional implantation of an LV assist device in a giant LV aneurysm.
